04 Jan Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
Lausanne, Switzerland, January 4th, 2019 – Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. No financial details are disclosed.
The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including controlled studies under IND by Novartis Institute of Biomedical Research. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye, including Dry Eye Disease.
The in-licensing of LME636, which will be renamed OCS-02, expands Oculis’ portfolio of novel topical therapies for major ophthalmic diseases, and offers Oculis the opportunity to address unmet medical needs of patients with potentially the first topical anti-TNF alpha therapy for ophthalmic indications.
Oculis plans to develop OCS-02 in parallel to its other ongoing pipeline programs. It will be supported by new funds raised in the extension of its Series B financing round, announced separately today.
Dr. Riad Sherif, CEO of Oculis said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases. We are looking forward to working with the ophthalmology community on the rapid development of this promising therapy.”
Dr. Riad Sherif, CEO
Louie-Anne Gauthier, VP Strategic Marketing, BD&L
Mark Swallow, Sylvie Berrebi, Marine Perrier
Citigate Dewe Rogerson
Tel: +44 207 638 9571